Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
作者信息
Antonarakis Emmanuel S
机构信息
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
出版信息
Asian J Androl. 2012 Jul;14(4):520-1. doi: 10.1038/aja.2012.45. Epub 2012 May 14.
Abstract
摘要
相似文献
1
Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.将主动免疫疗法与免疫检查点阻断相结合用于晚期前列腺癌的治疗。
Asian J Androl. 2012 Jul;14(4):520-1. doi: 10.1038/aja.2012.45. Epub 2012 May 14.
2
Prostate cancer immunotherapy.前列腺癌免疫疗法。
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
3
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.T 细胞分析显示，CD4+CTLA-4+T 细胞频率高是前列腺癌 GVAX/ipilimumab 治疗后生存的主要预测因素。
Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.
4
Intensifying tumour immunity through combination therapy.通过联合疗法增强肿瘤免疫。
Lancet Oncol. 2012 May;13(5):440-2. doi: 10.1016/S1470-2045(12)70051-7. Epub 2012 Feb 10.
5
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.序贯 CTLA-4 阻断与基于细胞的免疫疗法治疗前列腺癌。
J Transl Med. 2013 Apr 4;11:89. doi: 10.1186/1479-5876-11-89.
6
Ipilimumab in prostate cancer.依匹木单抗治疗前列腺癌。
Expert Opin Biol Ther. 2013 Feb;13(2):303-13. doi: 10.1517/14712598.2012.754421. Epub 2012 Dec 25.
7
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.依匹木单抗联合前列腺特异性抗原靶向的痘病毒疫苗治疗转移性去势抵抗性前列腺癌：一项 I 期剂量爬坡试验。
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.
8
Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.
Nat Rev Urol. 2012 May 8;9(6):302-3. doi: 10.1038/nrurol.2012.103.
9
Immunotherapy in prostate cancer: review of the current evidence.前列腺癌的免疫疗法：当前证据综述
Clin Transl Oncol. 2015 May;17(5):339-57. doi: 10.1007/s12094-014-1259-6. Epub 2014 Dec 6.
10
Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?伊匹单抗的免疫检查点阻断在前列腺癌中有作用吗？
Cancer Med. 2013 Apr;2(2):243-52. doi: 10.1002/cam4.64. Epub 2013 Feb 24.
引用本文的文献
1
The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review.溶瘤病毒疗法在头颈癌治疗中的潜力：综述
Int J Mol Sci. 2024 Dec 3;25(23):12990. doi: 10.3390/ijms252312990.
2
Identification of Prostate Cancer Risk Genetics Biomarkers Based on Intergraded Bioinformatics Analysis.基于综合生物信息学分析的前列腺癌风险遗传生物标志物鉴定
Front Surg. 2022 Mar 17;9:856446. doi: 10.3389/fsurg.2022.856446. eCollection 2022.
3
Overview of virus and cancer relationships. Position paper.病毒与癌症关系概述。立场文件。
Rev Esp Quimioter. 2021 Dec;34(6):525-555. doi: 10.37201/req/058.2021. Epub 2021 Aug 5.
4
Oncolytic virus immunotherapy: future prospects for oncology.溶瘤病毒免疫治疗：肿瘤学的未来前景。
J Immunother Cancer. 2018 Dec 4;6(1):140. doi: 10.1186/s40425-018-0458-z.
5
Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.去势抵抗性前列腺癌进展机制与治疗的最新进展
Onco Targets Ther. 2018 May 28;11:3167-3178. doi: 10.2147/OTT.S159777. eCollection 2018.
6
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.利用免疫监视：癌症免疫治疗的当前进展与未来方向
Immunotargets Ther. 2014 Dec 4;3:151-65. doi: 10.2147/ITT.S37790. eCollection 2014.
7
8
Immunotherapy and immune evasion in prostate cancer.前列腺癌的免疫治疗与免疫逃逸。
Cancers (Basel). 2013 May 24;5(2):569-90. doi: 10.3390/cancers5020569.
9
Immunotherapy for prostate cancer enters its golden age.前列腺癌免疫治疗进入黄金时代。
Clin Med Insights Oncol. 2012;6:263-73. doi: 10.4137/CMO.S7475. Epub 2012 Jul 10.
本文引用的文献
1
Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.联合免疫和雄激素靶向治疗：前列腺癌免疫治疗的新策略
Curr Opin Oncol. 2012 May;24(3):258-65. doi: 10.1097/CCO.0b013e32835205a0.
2
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.依匹木单抗联合前列腺特异性抗原靶向的痘病毒疫苗治疗转移性去势抵抗性前列腺癌：一项 I 期剂量爬坡试验。
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.
3
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.粒细胞-巨噬细胞集落刺激因子转导的同种异体前列腺癌细胞联合 ipilimumab 治疗转移性去势抵抗性前列腺癌患者：一项 1 期剂量递增试验。
Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.
4
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.依匹单抗联合达卡巴嗪治疗未经治疗的转移性黑色素瘤。
N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.
5
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
6
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
7
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.抗程序性死亡-1 单药（MDX-1106）治疗难治性实体瘤的 I 期研究：安全性、临床活性、药效学和免疫相关性。
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
8
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
9
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.一项使用人抗CTLA-4对激素难治性前列腺癌患者进行CTLA-4阻断的试点试验。
Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318.
Zotero 插件